As of 2025-06-30, the EV/EBITDA ratio of Cytokinetics Inc (CYTK) is -7.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CYTK's latest enterprise value is 4,544.75 mil USD. CYTK's TTM EBITDA according to its financial statements is -571.84 mil USD. Dividing these 2 quantities gives us the above CYTK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 13.3x | 12.7x |
| Forward P/E multiples | 17.9x - 27.3x | 22.4x |
| Fair Price | (90.41) - (68.58) | (89.04) |
| Upside | -372.6% - -306.8% | -368.5% |
| Date | EV/EBITDA |
| 2025-06-27 | -7.95 |
| 2025-06-26 | -8.10 |
| 2025-06-25 | -7.94 |
| 2025-06-24 | -8.00 |
| 2025-06-23 | -7.84 |
| 2025-06-20 | -7.80 |
| 2025-06-18 | -7.86 |
| 2025-06-17 | -7.82 |
| 2025-06-16 | -8.08 |
| 2025-06-13 | -8.20 |
| 2025-06-12 | -7.96 |
| 2025-06-11 | -7.94 |
| 2025-06-10 | -8.24 |
| 2025-06-09 | -7.94 |
| 2025-06-06 | -7.77 |
| 2025-06-05 | -7.72 |
| 2025-06-04 | -7.79 |
| 2025-06-03 | -7.71 |
| 2025-06-02 | -7.54 |
| 2025-05-30 | -7.50 |
| 2025-05-29 | -7.56 |
| 2025-05-28 | -7.35 |
| 2025-05-27 | -7.40 |
| 2025-05-23 | -7.40 |
| 2025-05-22 | -7.39 |
| 2025-05-21 | -7.56 |
| 2025-05-20 | -7.84 |
| 2025-05-19 | -7.44 |
| 2025-05-16 | -7.50 |
| 2025-05-15 | -7.25 |
| 2025-05-14 | -7.29 |
| 2025-05-13 | -7.41 |
| 2025-05-12 | -7.73 |
| 2025-05-09 | -7.64 |
| 2025-05-08 | -7.81 |
| 2025-05-07 | -7.92 |
| 2025-05-06 | -8.12 |
| 2025-05-05 | -8.68 |
| 2025-05-02 | -8.82 |
| 2025-05-01 | -9.99 |
| 2025-04-30 | -9.97 |
| 2025-04-29 | -9.65 |
| 2025-04-28 | -9.63 |
| 2025-04-25 | -9.47 |
| 2025-04-24 | -9.44 |
| 2025-04-23 | -8.96 |
| 2025-04-22 | -8.92 |
| 2025-04-21 | -8.94 |
| 2025-04-17 | -9.27 |
| 2025-04-16 | -9.20 |